The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.

Amneal Pharmaceuticals reported promising interim results from its ELEVATE-PD study for CREXONT, a new extended-release Parkinson's disease treatment. The study showed significant improvements in patient 'Good On' time, reduced 'Off' time, and enhanced motor symptom control across 55 patients.

Amneal Pharmaceuticals executives Chirag Patel and Tasos Konidaris will participate in two upcoming healthcare investor conferences in December 2025 and January 2026, presenting the company's strategic outlook.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.

Amneal Pharmaceuticals submitted a Biologics License Application (BLA) to the FDA for a biosimilar to XOLAIR, developed with Kashiv BioSciences. The potential entry targets the $4+ billion U.S. market for omalizumab, with expected milestone charges and future growth opportunities.

The global ophthalmic packaging market is expected to grow from $12.38 billion in 2026 to $23.65 billion by 2034, driven by increasing eye diseases, aging populations, and technological advancements in packaging solutions.

Global binge eating disorders market is growing due to advances in diagnostics, digital health technologies, and personalized treatments, with North America leading market expansion despite challenges like social stigma and high therapy costs.

Knight Therapeutics filed a New Drug Submission for CREXONT®, an innovative extended-release Parkinson's disease treatment, with Health Canada. The drug aims to improve patient treatment by offering longer drug absorption and fewer daily doses.

Thérapeutique Knight has submitted a new drug submission for CREXONT®, a novel oral carbidopa/levodopa formulation for Parkinson's disease treatment, to Health Canada. The drug aims to provide improved therapeutic options with extended-release capsules and has demonstrated promising clinical trial results.

Amneal Pharmaceuticals announced positive results from a clinical trial evaluating a biosimilar candidate to XOLAIR(R) (omalizumab), developed by Kashiv BioSciences. The study met its primary and secondary endpoints, and Amneal holds exclusive U.S. commercialization rights for the product, which is expected to be filed with the FDA in Q4 2025.